Featured Research

from universities, journals, and other organizations

New Drug To Fight Pneumonia And Meningitis? Scientists Cripple Critical Pneumococcal Proteins

Date:
February 2, 2009
Source:
Wiley-Blackwell
Summary:
Researchers have introduced a highly promising new approach for the development of drugs to treat pneumococci, which cause pneumonia and meningitis. They copied the choline architecture of the pneumococcal cell wall. They were then able to trap the choline-binding proteins that have a critical effect on the infectiousness of pneumococcal bacteria.

Scientists have copied the choline architecture of the pneumococcal cell wall. They were then able to trap the choline-binding proteins that have a critical effect on the infectiousness of pneumococcal bacteria.
Credit: Copyright Wiley-VCH

Approximately 1.6 million people die worldwide every year as a result of pneumococcal infection, which causes grave illnesses, including pneumonia, meningitis, and middle-ear infections. Children and the elderly are especially at risk. Vaccines are only effective against a few of the pneumococcal types and increasing resistance to antibiotics is making treatment more difficult.

Related Articles


Researchers led by Jesϊs M. Sanz at the Miguel Hernandez University (Elche, Spain) and Maarten Merkx at the Eindhoven University of Technology (Netherlands) have now introduced a highly promising new approach for the development of drugs to treat pneumococci.

As they report in the journal Angewandte Chemie, the scientists copied the choline architecture of the pneumococcal cell wall. They were thus able to trap the choline-binding proteins that have a critical effect on the infectiousness of pneumococcal bacteria.

The cell walls of pneumococci contain special polymers, called teichoic acids, that are equipped with phosphocholine groups and induce a characteristic choline architecture on the cell walls. The choline groups act as docking stations for a number of special proteins that are involved in important processes such as cell-wall division, the release of bacterial toxins, and adhesion to infected tissues. These choline-binding proteins (CBP) contain domains with multiple neighboring choline-binding sites. The protein LytA, for example, has a domain with four choline-binding sites.

If choline is added to a culture of pneumococci, the molecules occupy the choline binding sites of the CBPs so that the proteins can no longer bind to the cell walls of the pneumococci. Although the bacteria continue to multiply, the individual cells can no longer separate from each other, which results in long chains of linked cells. In addition, the toxin-releasing self-destruction (autolysis) typical of pneumococci at the end of their life cycle is stopped.

However, choline is not suitable for use as a drug because an effective dose would be far too high. The researchers thus developed the foundation for a new drug that binds CBP much more strongly than individual choline molecules.

Their trick: the drug imitates the choline architecture of the cell wall by presenting multiple choline groups. As a scaffold for their assembly of choline groups, the researchers chose to use dendrimers (tree-like branched molecules), attaching the choline groups to the tips of the “branches”. The choline ends can simultaneously occupy multiple choline binding sites of the CBP. The dendrimer frameworks are flexible enough to meet the spatial demands of the application.

The required dosage of this CBP inhibitor lies within the range that is acceptable for pharmaceuticals.


Story Source:

The above story is based on materials provided by Wiley-Blackwell. Note: Materials may be edited for content and length.


Journal Reference:

  1. Multivalent Choline Dendrimers as Potent Inhibitors of Pneumococcal Cell-Wall Hydrolysis. Angewandte Chemie International Edition, 2009, 48, 948%u2013951 DOI: 10.1002/anie.200803664

Cite This Page:

Wiley-Blackwell. "New Drug To Fight Pneumonia And Meningitis? Scientists Cripple Critical Pneumococcal Proteins." ScienceDaily. ScienceDaily, 2 February 2009. <www.sciencedaily.com/releases/2009/01/090128104629.htm>.
Wiley-Blackwell. (2009, February 2). New Drug To Fight Pneumonia And Meningitis? Scientists Cripple Critical Pneumococcal Proteins. ScienceDaily. Retrieved March 6, 2015 from www.sciencedaily.com/releases/2009/01/090128104629.htm
Wiley-Blackwell. "New Drug To Fight Pneumonia And Meningitis? Scientists Cripple Critical Pneumococcal Proteins." ScienceDaily. www.sciencedaily.com/releases/2009/01/090128104629.htm (accessed March 6, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, March 6, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Bupa Eyes India Healthcare Opportunities

Bupa Eyes India Healthcare Opportunities

Reuters - Business Video Online (Mar. 5, 2015) — Bupa is hoping to expand in India&apos;s fast-growing health insurance market, once a rule change on foreign investment is implemented. The British private healthcare group&apos;s CEO tells Grace Pascoe why it&apos;s so keen on the new opportunity. Video provided by Reuters
Powered by NewsLook.com
Doctor in Your Pocket Is Getting Smarter

Doctor in Your Pocket Is Getting Smarter

Reuters - Business Video Online (Mar. 5, 2015) — Mobile apps are turning smartphones into a personal doctors, with users able to measure heart rate, blood pressure and even blood sugar. But will it change our behaviour? Ivor Bennett reports from the Mobile World Congress in Barcelona. Video provided by Reuters
Powered by NewsLook.com
AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

Newsy (Mar. 5, 2015) — AbbVie announced Wednesday it will buy cancer drugmaker Pharmacyclics in a $21 billion deal. Video provided by Newsy
Powered by NewsLook.com
Toddlers Drinking Coffee? Why You Shouldn't Share Your Joe

Toddlers Drinking Coffee? Why You Shouldn't Share Your Joe

Newsy (Mar. 5, 2015) — A survey of Boston mothers and toddlers found that 15 percent of two-year-olds drink coffee and 2.5 percent of 1-year-olds. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins